Remedy Cell moved its secretome-based therapy, RC-0315, into first-in-human development for idiopathic pulmonary fibrosis (IPF), according to company updates. The approach uses a “secretome” product—bioactive molecules released by cells—including proteins, enzymes, growth factors, and extracellular-vesicle components such as exosomes. The decision places Remedy in an early-stage cohort focused on complex lung disorders where single-pathway drugs have struggled to deliver durable benefit. As the program begins, investigators will assess safety, tolerability, and early pharmacodynamic signals. For biotech observers, this is another example of modality diversification in fibrotic disease, with developers testing whether cell-derived extracellular signals can modulate multiple injury and repair pathways at once.